drugset / Trial / NCT07395739
A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104
RandomizedParallel-groupTriple-blindPrevention
Summary
A randomized, double-blinded, positive-controlled clinical trial will be conducted to observe the safety and immunogenicity of DX-104 in adults 18 to 50 years of age.
Timeline
- Start
- 2026-03-20
- Primary completion
- 2027-05-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bexsero | Vaccine | 0.5 ml | Intramuscular |
| Subject | DX-104 | Unknown | 0.5 ml | Intramuscular |